Condition 1: Gastrointestinal side effects of glucocorticoid pulse therapy in MS relapse. Condition 2: Multiple sclerosis. Condition 3: Gastrointestinal symptoms. Glucocorticoids and synthetic analogues Multiple sclerosis Disease of digestive system, unspecified
Conditions
Interventions
Intervention 1: Intervention group: During the period of receiving pulse glucocorticoid therapy, patients will take one 40 mg famotidine tablet (manufatured by Shahre Daru) daily. Intervention 2: Cont
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Patients with Relapsing-Remitting Multiple Sclerosis aged 18 to 65 years, hospitalized in the Neurology Department of Sina Hospital Candidates for receiving pulse corticosteroid therapy at a dose of 1 gram per day for at least 3 days Written and informed consent obtained from the patient for participation in the study
Exclusion criteria
Exclusion criteria: Presence or history of peptic ulcer disease (PUD), gastroesophageal reflux disease (GERD), or inflammatory bowel diseases such as colitis and Crohn's disease Concurrent use of other medications that cause gastrointestinal mucosal damage and increase the risk of ulcers and bleeding, such as oral corticosteroids, non steroid anti-inflammatory drugs, anticoagulants, antiplatelets Use of acid-suppressing medications such as proton pump inhibitors and histamin type 2 receptor antagonists within the past week Severe chronic kidney disease (CrCl < 30) or moderate to severe hepatic failure (Child-Pugh score B and C) Pregnancy and breastfeeding Patients who, in addition to pulse corticosteroids therapy, are simultaneously receiving IVIG or undergoing plasma exchange.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Stool characteristics. Timepoint: At the time of admission, at the time of discharge, two weeks after discharge. Method of measurement: Based on the score in the Abdominal symptoms questionnaire: none, mild, moderate, quite a lot, severe, very severe, unbearable.;Antacid consumption as needed. Timepoint: At the time of discharge. Method of measurement: Recording and assessment of the amount of antacid consumed.;Abdominal pain. Timepoint: At the time of admission, at the time of discharge, two weeks after discharge. Method of measurement: Based on the score in the Abdominal symptoms questionnaire: none, mild, moderate, quite a lot, severe, very severe, unbearable.;Epigastric pain. Timepoint: At the time of admission, at the time of discharge, two weeks after discharge. Method of measurement: Based on the score in the Abdominal symptoms questionnaire: none, mild, moderate, quite a lot, severe, very severe, unbearable.;Heartburn. Timepoint: At the time of admission, at the time of discharge, two weeks after discharge. Method of measurement: Based on the score in the Abdominal symptoms questionnaire: none, mild, moderate, quite a lot, severe, very severe, unbearable.;Regurgitation. Timepoint: At the time of admission, at the time of discharge, two weeks after discharge. Method of measurement: Based on the score in the Abdominal symptoms questionnaire: none, mild, moderate, quite a lot, severe, very severe, unbearable.;Abdominal rumbling. Timepoint: At the time of admission, at the time of discharge, two weeks after discharge. Method of measurement: Based on the score in the Abdominal symptoms questionnaire: none, mild, moderate, quite a lot, severe, very severe, unbearable.;Bloating. Timepoint: At the time of admission, at the time of discharge, two weeks after discharge. Method of measurement: Based on the score in the Abdominal symptoms questionnaire: none, mild, moderate, quite a lot, severe, very severe, unbearable.;Nausea. Timepoint: At the time of admission, at th | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHooshyar Honarmand
Tehran University of Medical Sciences
Outcome results
None listed